Ligand-independent activation of c-Met by fibronectin and α5 Β1-integrin regulates ovarian cancer invasion and metastasis

Oncogene

Volumn 30, Issue 13, 2011, Pages 1566-1576

  Mitra, A K ^a   Sawada, K ^a   Tiwari, P ^a   Mui, K ^a   Gwin, K ^a   Lengyel, E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 1 integrin; c Met; FAK; fibronectin; ovarian cancer; Src

Indexed keywords

FIBRONECTIN; FOCAL ADHESION KINASE; SCATTER FACTOR RECEPTOR; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL ADHESION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; CELL LINE, TUMOR; FEMALE; FIBRONECTINS; FOCAL ADHESION KINASE 1; HUMANS; INTEGRIN ALPHA5BETA1; LIGANDS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 79953220086     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.532     Document Type: Article

References (38)

1. Avraamides CJ, Garmy-Susini B, Varner JA. (2008). Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617.
2. Bhaskar V, Zhang D, Fox M, Seto P, Wong M, Wales PE et al. (2007). A function blocking anti-mouse integrin a5b1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 5: 1-11.
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925. (Pubitemid 37493640)
4. Brader KR, Wolf JK, Hung M-C, Yu D, Crispens MA, van Golen KL et al. (1997). Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res 3: 2017-2024. (Pubitemid 27505128)
5. Caswell PT, Spence HJ, Parsons M, White DP, Clark K, Cheng KW et al. (2007). Rab25 associates with a5b1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 13: 496-510. (Pubitemid 47514517)
6. Chan P-C, Chen SY, Chen C-H, Chen HC. (2006). Crosstalk between hepatocyte growth factor and integrin signaling pathways. J Biomed Sci 13: 215-223.
7. 125fak*. J Biol Chem 269: 20567-20574.
8. Chen SY, Chen H-C. (2006). Direct interaction of focal adhesion kinase (FAK) with met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 26: 5155-5167. (Pubitemid 43955827)
9. Francis SE, Goh KL, Hodivala-Dilke KM, Bader BL, Stark M, Davidson D et al. (2002). Central roles of a5b1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 22: 927-933. (Pubitemid 34655219)
10. Franke FE, Von Georgi R, Zygmunt M, Munstedt K. (2003). Association between fibronectin expression and prognosis in ovarian carcinoma. Anticancer Res 23: 4261-4268.
11. Giancotti FG, Tarone G. (2003). Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 19: 173-206. (Pubitemid 37487347)
12. Hafter R, Klaubert W, Gollwitzer R, Graeff H. (1984). Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Thromb Haemost 35: 53-64. (Pubitemid 14085626)
13. Huttenlocher A, Lakonishok M, Kinder M, Wu S, Truong T, Knudsen K et al. (1998). Integrin and cadherin synergy regulates contact inhibition of migration and motile activity. 141: 515-526.
14. Hynes RO. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687. (Pubitemid 35283958)
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ et al. (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
16. Jin E, Choi Y, Park E, Bang O, Kang S. (2007). MMP-2 functions as a negative regulator of chondrogenic cell condensation via down-regulation of the FAK -integrin b1 interaction. Devel Biol 308: 474-484. (Pubitemid 47223113)
17. Kenny HA, Lengyel E. (2009). MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 8: 683-688.
18. 1with the central cell-binding domain of fibronectin. Am J Pathol 156: 1345-1362. (Pubitemid 30660012)
19. Lengyel E. (2010). Ovarian cancer development and metastasis. Am J Pathol 177: 1053-1064.
20. 1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 65: 2712-2721. (Pubitemid 40490072)
21. Mitra SK, Schlaepfer D. (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516-523. (Pubitemid 44332916)
22. Nakamura Y, Matsubara D, Goto A, Ota S, Sachiko O, Ishikawa S et al. (2008). Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci 99: 14-22. (Pubitemid 350239026)
23. Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A et al. (2008). Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and b1-integrin on the cell surface. J Biol Chem 283: 1463-1472.
24. Ricono JM, Huang M, Barnes LA, Lau SK, Weis S, Schlaepfer D et al. (2009). Specific cross-talk between epidermal growth factor receptor and integrin avb5 promotes carcinoma cell invasion and metastasis. Cancer Res 69: 1383-1391.
25. Rusciano D, Lorenzoni P, Burger MM. (1996). Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity. J Biol Chem 271: 20763-20769. (Pubitemid 26281861)
26. Saga Y, Mizukami H, Suzuki H, Urabe M, Kume A, Nakamura T et al. (2001). Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther 8: 1450-1455. (Pubitemid 32994655)
27. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner E, Tretiakova MS et al. (2008). Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68: 2329-2339. (Pubitemid 351521807)
28. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny HA, Salgia R et al. (2007). C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67: 1670-1680.
29. Taverna D, Hynes RO. (2001). Reduced blood vessel formation and tumor growth in a5-integrin-negative teratocarcinomas and embry-oid bodies. Cancer Res 61: 5255-5261. (Pubitemid 32681561)
30. Trusolino L, Bertotti A, Comoglio PM. (2001). A signaling adapter function for a6b4 integrin in the control of HGF-dependent invasive growth. Cell 107: 643-654. (Pubitemid 34014865)
31. Vuori K, Ruoslahti E. (1994). Association of insulin receptor substrate-1 with integrins. Science 266: 1576-1578.
32. Wang R, Kobayashi R, Bishop M. (1996). Cellular adherence elicits ligand-independent activation of the Met cell -surface receptor. Proc Natl Acad Sci USA 93: 8425-8430. (Pubitemid 26269574)
33. 1 integrin on blood vessels in tumors. Am J Pathol 167: 193-211. (Pubitemid 40884781)
34. Wong AST, Roskelley CD, Pelech SL, Miller D, Leung PCK, Auersperg N. (2004). Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 299: 248-256. (Pubitemid 39078399)
35. 5 integrin-deficient mice. Development 119: 1093-1105. (Pubitemid 23358579)
36. Yokoyama Y, Sedgewick G, Ramakrishnan S. (2007). Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res 67: 10813-10822. (Pubitemid 350145910)
37. Yu D, Wolf JK, Scanlon M, Price JE, Hung M-C. (1992). Enhanced c-erb B-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898. (Pubitemid 23077880)
38. Zillhardt M, Christensen J, Lengyel E. (2010). An orally available small molecule inhibitor of c-Met, PF-2341066, reduces tumor burden in a pre-clinical model of ovarian cancer metastasis. Neoplasia 12: 1-10.